Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Eaton, C., J. Wells, I. Holen, P. Croucher, and F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.

Eaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.